News | July 31, 2024
Boehringer Ingelheim acquires Nerio Therapeutics for US$ 1.3bn
Boehringer Ingelheim aims to develop this program as a potential key centerpiece component for its immuno-oncology portfolio
Boehringer Ingelheim aims to develop this program as a potential key centerpiece component for its immuno-oncology portfolio
The Central government’s decision to exempt three more cancer medicines from customs duty is a commendable step towards making cancer drugs more affordable
Phase III ARANOTE trial met primary endpoint, significantly increasing radiological progression-free survival (rPFS) with NUBEQA plus androgen deprivation therapy (ADT) compared to placebo plus ADT
Finance Minister Nirmala Sitharaman is set to present the full budget for the current financial year on July 23
Doxorubicin Hydrochloride Liposome Injection (RLD Doxil) had estimated annual sales of USD 42 million in the U.S. (IQVIA MAT May 2024)
Acquisition to expand Lilly's immunology pipeline with oral integrin therapies
Olverembatinib, a novel drug developed by Ascentage Pharma with support from the National Major New Drug Development program
Utidelone can penetrate BBB due to its unique physicochemical characteristics and insusceptibility to P-glycoprotein-mediated efflux
Acquisition provides Ligand with the royalty rights to QARZIBA, a highly differentiated, commercial oncology drug marketed in 35 countries by global pharmaceutical company Recordati S.p.A.
Partners with Yifan Pharmaceutical to launch Synovian injection for osteoarthritis in China
Subscribe To Our Newsletter & Stay Updated
